Tools to encourage the development of integrated thinking
Given the pace of innovation in drug development, a major challenge for Clinical Pharmacology in biotech and pharma is how it maintains relevance as a key integrator and applier of knowledge to accelerate the development of medicines.
December 10, 2013
We are all in this together! Paths to better collaboration for drug discovery and development
Patrick Smith and Craig Rayner will be presenting the keynote address at the ASCEPT 2013 Annual Scientific Meeting, in Melbourne Australia.
November 14, 2013
Cenicriviroc PK/PD Analyses Presented at European AIDS Conference
d3 medicine contributed to exposure-response analyses and rationale to support Cenicriviroc (Tobira Therapeutics) dose selection for Phase 3. The results of the PK/PD investigations will be presented by the Tobira team at the European AIDS Conference.
October 26, 2013
Wall Street Journal: Arch Biopartners Appoints Patrick Smith and Craig Rayner as Drug Development Advisors
Arch Biopartners Appoints Patrick Smith and Craig Rayner as Drug Development Advisors. In this capacity, Dr. Smith and Dr.
September 16, 2013
New Publications: Clinical Implications of Hepatitis C Protease Inhibitor Drug Interactions
d3 medicine Investigators have recently published 4 manuscripts which lend important new insights into the emerging and challenging area of HCV small molecule therapeutics, where drug-drug interactions are of significant concern.
August 25, 2013
New Publications: Clinical pharmacology insights into Oseltamivir
Two publications on oseltamivir clinical PK/PD have been published ahead of print in Antimicrobial Agents and Chemotherapy.
May 21, 2013
BioMelbourne Network BioBriefing: Driving Global Best Practice in Drug Development in Victoria: Malaria Case Study
Dr. Craig Rayner will chair a BioMelbourne Network Biobriefing: Driving Global Best Practice in Drug Development in Victoria:Malaria Case Study.